Clinical Trial Update: Study on Immunogenicity, Reactogenicity and Safety of the VACΔ6 Vaccine in Volunteers Aged 18-60 Years [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial evaluating immunogenicity, reactogenicity, and safety of the VACΔ6 vaccine in adults 18-60; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cowpox
• Monkeypox
• Smallpox
• Vaccinia Virus Infection

Drugs mentioned

• VACΔ6

Snippet

Sponsor: Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector" | Conditions: Smallpox, Monkeypox | Phase 2, Phase 3 | Status: COMPLETED